Mint Tower Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Mint Tower Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-187,443	Closed	-$570K	–	175
2024 Q4	$570K	Buy	187,443 +127,443	+212%	+$555K	0.14%	70
2024 Q3	$311K	Buy	+60,000	New	+$298K	0.1%	75

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mint Tower Capital Management's RVNC Position: Q1 2025 in Review

Mint Tower Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 187,443 shares — an estimated $570K sold.

Mint Tower Capital Management first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $570K in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Mint Tower Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Mint Tower Capital Management sold 187,443 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $570K.
Mint Tower Capital Management first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
Mint Tower Capital Management's Revance Therapeutics, Inc. position peaked at $570K in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Mint Tower Capital Management's 13F filing for Q1 2025, filed 15 May 2025.